胰腺癌靶向治疗药物的现状和展望  

Current status and prospect of targeted therapeutic drugs for pancreatic cancer

作　　者：高立科 薛栋[2] Gao Like;Xue Dong(Clinical Medical College of Binzhou Medical College,Yantai 264003,China;Department of Hepatobiliary Surgery,Binzhou People's Hospital,Binzhou 256610,China)

机构地区：[1]滨州医学院临床医学院,烟台264003 [2]滨州市人民医院肝胆外科,滨州256610

出　　处：《中国医师杂志》2022年第6期957-960,共4页Journal of Chinese Physician

基　　金：滨州医学院科研启动基金(BY2015KYQD25);滨州市科技发展计划政策引导类项目(2014ZC0120);滨州市人民医院院级课题(YJKTZR202105)。

摘　　要：胰腺癌是一种致命的疾病,这种肿瘤类型的所有分期患者的生存率都很低,大多数患者死于化疗耐药的转移性疾病。吉西他滨作为胰腺癌的标准治疗药物已有20多年时间,但作为单一药物吉西他滨并不能完全治愈胰腺癌。在过去的几十年里,人们在开发有效的治疗胰腺癌的方法上做出了巨大的努力。本篇综述回顾了近年来临床对胰腺癌靶向治疗药物的研究现状,同时介绍针对胰腺肿瘤常见分子特征的药物及基于转移机制的联合治疗方法。在分子靶向的时代,针对胰腺癌的靶向治疗有望成为治疗的突破口。Pancreatic cancer is a fatal disease.The survival rate of patients with all stages of pancreatic cancer is very low,and most patients die of chemotherapy-resistant metastatic diseases.Gemcitabine has been used as the standard treatment for pancreatic cancer for more than 20 years,but as a single drug,gemcitabine can not completely cure pancreatic cancer.In the past decades,great efforts have been made to develop effective treatments for pancreatic cancer.This review describes the research status of targeted therapy drugs for pancreatic cancer in recent years,introduces drugs for common molecular characteristics of pancreatic cancer,and develops combined therapy based on metastasis mechanism.In the era of molecular targeting,targeted therapy for pancreatic cancer is expected to become a breakthrough in the treatment.

关 键 词：胰腺肿瘤 吉西他滨 分子靶向治疗 

分 类 号：R735.9[医药卫生—肿瘤]